Glenmark Pharma`s arm recalls 98,307 packs of Mometasone Furoate Topical Solution
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Glenmark Pharmaceuticals’ fully owned subsidiary -- Glenmark Pharmaceuticals Inc., USA (Glenmark) is recalling 98,307 packs of Mometasone Furoate Topical Solution, a medication used to treat skin conditions such as eczema, psoriasis, allergies, and rash. The company is recalling the lot, which rolled out from the company's Baddi (Himachal Pradesh) plant, due to Defective Container.
The company initiated the nationwide recall, which the US health regulator classified as Class III, on June 16, 2022. A Class III recall is initiated in a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences. The US generic drug market was estimated to be around $115.2 billion in 2019. It is by far the largest market for pharmaceutical products in the world.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
